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The human immune system is a vital mechanism that protects the host from outside threats. 
The two main branches of this system, consisting of innate and adaptive immunity, aid the 
host when dangers of both imminent and protracted nature occur. Innate lymphoid cells (ILC) 
play a key role in innate immunity and are classified into distinct groups based on their 
function, transcriptional profile and development. Their discovery is young, with much 
research needed to understand all aspects of their phenotype, genotype, behavior in 
homeostasis and disease.  
This thesis describes the breakthroughs my collaborators and I were able to reach during my 
five years of doctoral studies, in order to better understand the biology and physiology of 
ILC. In the first part of this thesis I describe the history and classification of ILC, the efforts 
being done so far by the field to understand their development, and the possible combinations 
of changes in ILC status, known as plasticity or trans-differentiation properties of ILC under 
particular environments or stimuli. As Paper II’s results are based on a cohort of 
Inflammatory Bowel Disease (IBD) samples, and in Paper I we analyze ILC in intestinal 
biopsies from IBD patients, I also outline the main characteristics representing this disorder 
while focusing on the role of ILC in IBD. 
Next, after defining the aim of my studies, I describe how the data was obtained, as a big part 
of my work consisted in learning how to handle methods and technologies such as flow 
cytometry, fluorescence-activated cell sorting (FACS) and single cell RNA sequencing, 
among others.  
Finally, a discussion of the results is aimed at highlighting the major breakthroughs achieved. 
In Paper I, we set out to better understand the function of the Ikaros family of transcription 
factors in ILC, focusing our efforts on IKZF3 (encoding Aiolos) and its role in ILC trans-
differentiation via a drug-induced silencing approach with the immune-modulatory agent 
lenalidomide. In Paper II, a large cohort of IBD samples was analyzed in order to find 
disturbances in peripheral blood ILC protein expression. We were able to uncover differences 
in several activation proteins in the IBD cohort, when compared to a like-sized cohort of 
samples from healthy controls. In Paper III, a big effort was put into implementing Smart-
seq2 RNA sequencing technology to a large number of ILC from a variety of tissues. This 
allowed us to better understand the heterogeneity of ILC in the circulation, secondary 
lymphoid and mucosal tissues. We generated a large dataset that will require time to be 
exploited in full, constituting a roadmap for future studies aimed at understanding human ILC 
biology and function.  
In summary, the work presented in this thesis provides findings and datasets that have the 
potential to advance the ILC field.  
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Throughout life, our body is constantly under attack, and more often than not we are unaware 
of this fact. We ought to be grateful to our defense system, that protects us from a variety of 
threats, including bacteria, viruses, fungi, protozoa, worms and other pathogens. We are able 
to exploit this ancient mechanism thanks to evolution, which in its broadest sense, took one 
billion years to develop 1 via a very slow process, from phagocytosis in protozoa to the more 
complex immune system of mammals 2. In this thesis, I will discuss my research on several 
cogs in this vital machinery called the innate immune system, comprised of a variety of cells 
ready to defend us from foreign attacks within minutes. One important piece of this early 
defense involves innate lymphoid cells (ILC), the focus of my research. 
 
1.1 INNATE LYMPHOID CELLS 
Human innate lymphoid cells (ILCs) are a type of lymphocyte lacking rearranged antigen 
specific receptors, often regarded as the innate counterpart of T cells 34. ILCs provide a rapid 
immune response upon threat, regulating inflammation by quickly releasing cytokines, before 
T cells take over. So far, they have been reported as residing in many tissues (i.e. adipose 
tissue 5, tonsils 6, gut 7, thymus 8, skin 9, liver 10, lung 11, uterus 12, bone marrow 13 and nasal 
polyps 14) and , at low frequency, in circulation 15.  
Their discovery spans over five decades 16, with most findings made during the last 10 years 
17. In the early 1970’s, a series of papers and reports 18 describing “natural” cytotoxic 
reactivity to cancer in humans 19 and mouse 20 were published, coining the cells responsible 
for this activity as “N” cells 20. In 1975, at Karolinska Institutet, similar results were reported 
21, changing the name of the cells to natural killer (NK) cells. After these discoveries, the next 
breakthrough in the innate lymphocyte field was made in the late 90’s, with the discovery of 
lymphoid tissue inducer cells 22. It took an additional 10 years for the field to realize that the 
innate lymphoid cell family was more heterogeneous than once thought, with a series of 
discoveries ranging from defining transcription factor differences among subsets 23, to innate 
type 2 cytokine producers 24,25,26 and finally the identification of ILC progenitors 27,28, 
providing proof of NK cells being developmentally different than the rest of ILCs. During the 
current decade, a number of novel discoveries were made in the field, shedding more light to 
the innate lymphoid cell biology, with a proposal for uniform nomenclature in 2013 29. 
Recently, smaller novel ILC subsets are continuously being discovered 6, but ILCs are now 




Figure 1. Classification and immune function of ILC. Reproduced with permission from Vivier et al. 
2018. Cell 17.  
 
1.1.1 ILC1 and NK cells 
ILC1 are commonly defined as IFN-γ producing cells 17, and are dependent on the 
transcription factor T-bet (encoded by TBX21) for their development. In a recent study 
identifying the RNA transcripts of ILCs at the single cell level 6, other transcription factors 
have been reported to be differentially expressed by ILC1, including Aiolos (encoded by 
IKZF3), and LEF-1. Their role in ILC1 development is still not clear, and studies to elucidate 
this are needed since ILC1 are very heterogeneous, and the least characterized ILC subset. 
ILC1 are considered as the innate counterparts of T helper 1 (Th1) cells 3, since they mirror 
their cytokine capabilities and transcription factor profile. ILC1 are generally non-cytotoxic, 
producing little granzyme B and no perforin 30. In addition to IFN-γ, ILC1 also produce TNF 
31 upon IL-12 and IL-18 stimulus 30, cytokines produced by dendritic (DC) cells and 
monocytes under inflammatory conditions 32. ILC1 produce IFN-γ, which inhibits viral 
replication and activate macrophages, which in turn increase their phagocytic activity and 
upregulate major histocompatibility complexes for antigen presentation, in order to initiate an 
adaptive response 33. In the mouse, intracellular pathogens such and Toxoplasma gondii and 
Salmonella enterica were shown to be cleared by IFN-γ releasing ILC1 27,34. 
A subgroup of ILC1 was discovered recently in the intestinal epithelium 35. Intraepithelial 
ILC1 express T-bet, but lack the defining ILC marker, CD127. Interestingly, they also 
express eomesodermin (encoded by EOMES) and require NFIL3 (also known as E4BP4 36) 
for their development.  
As ILC1 are defined as lacking key surface markers expressed by other ILC groups (i.e. 
CRTH2, CKIT, NKp44), and the expression of its defined transcription factor, T-bet, is 
heterogenous within the group, its existence has been questioned 37,38,39, mainly by one study 
performing mass cytometry (CyTOF) analysis of 30 surface markers, which failed to identify 
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ILC1 as a separate cluster through t-distributed stochastic neighbor embedding analysis (t-
SNE) 40. In addition to this, single cell RNA sequencing (scRNAseq) 6 and surface protein 
staining 15 revealed expression of transcripts normally linked to T cells (i.e. CD4, CD5, CD8, 
CD28 and some CD3 chains) in ILC1, pointing toward the possibility of T cell contamination 
during ILC isolation/analysis. In contrast to this evidence, pushing ILC1 towards a T cell 
phenotype via cytokine treatment failed to up regulate surface CD3 or TCR expression 30, the 
defining markers of T cells. Finding a correct definition and understanding what makes up the 
ILC1 subset is still currently under research. Efforts in understanding how other transcription 
factors affect ILC1 development and differentiation might shed some light on this issue. 
NK cells, as mentioned above, were the first innate lymphoid cells to be discovered 21, thus, 
this subset has undergone much scrutiny and is so far the most defined ILC. In addition to T-
bet, NK cells depend on the transcription factor eomesodermin. They are generally divided 
into a CD56bright subset, abundant cytokine producers but only weakly cytotoxic before 
activation 41  and a CD56dim subset, that is mostly responsible for cytolytic activity and target 
cell killing 42. Recently, additional NK subsets have been defined in peripheral tissues 43. One 
of the features dividing NK cells from the rest of ILCs is their lack of high expression of the α 
chain of the IL-7 receptor (CD127) (although CD56bright express low levels), and their IL-7 
independence for development.  
NK cells are activated through their natural cytotoxicity receptors (NCR), which leads to viral 
antigen recognition 44 and tumor cell death 45. In humans, NKp44 (encoded by NCR2), 
NKp46 (encoded by NCR1) and NKp30 (encoded by NCR3) are expressed on the surface of 
the cells, while mouse NK cells only express NKp46. IFN-γ is released by NK cells upon 
NKp30 engagement by dendritic cells, making DCs release IL-12, IL-15 and IL-18 cytokines, 
thus promoting a positive feedback loop between NK cells and DCs, which triggers an 
adaptive system activation via Th1 cells and ultimately stopping viral replication and 
initiating infected cell death 46. Other receptors on NK cells surface, when activated, can 
trigger cytotoxic molecule release 47. Virally infected or tumor aberrant cells upregulate the 
expression of MHC class 1 proteins with high affinity for the NK cell activating receptor 
NKG2D, thus initiating target cell killing 48,49. Perforin molecules create a pore on the target 
cell that facilitates the entry of granzymes into the target cell’s cytoplasma, where they cleave 
caspases and other molecules, causing cell death 50.  
 
1.1.2 ILC2 
One of the first proofs of an innate cell with type 2 cytokine capabilities was reported in a 
study published in 2001, where IL-25-treated Rag2-/- mice were shown to produce IL-13 and 
IL-5 51. Since such mice lacked the machinery to create mature T and B cells, the only way 
for cells to react to an IL-25 stimulus was through the innate system. Other studies found that 
similar models lacking T and B cells cleared Nippostrongylus brasiliens infection via IL-13 
52,53. In 2010, three key studies identified innate cells capable of type 2 responses in a variety 
of tissues in mouse, and they coined such population nuocytes, after the 13th letter of the 
greek alphabet (nu), since they wanted to underline their IL-13 releasing capabilities 25,26,24. 
Shortly after, the same cells were identified in human tissues and in circulation 14, finally 
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changing the nomenclature to its current accepted form of ILC2 29.  
ILC2 are dependent on the transcription factor Gata-binding protein (GATA3) 54. In the 
mouse, the retinoic acid receptor RAR-related orphan receptor α (RORα) 55 is also needed for 
ILC2 development, while in human this is still under debate. As with all ILCs, they lack 
lineage markers and express IL-7Rα, and they are defined by a combined expression of the 
prostaglandin D2 receptor CRTH2, CD25 and CD161 proteins in humans 14, and CD90, SCA-
1, ICOS and KLRG1 in mice 25,26,24. They produce type 2 cytokines IL-4, IL-5, IL-9 and IL-
13, but also IL-6, IL-8 and GM-CSF. In the mouse, amphiregulin (AREG) has also been 
detected 56,57. ILC2 are activated by soluble factors like lipid mediators 58,59, cell surface 
ligands (CD30, ICOS) and cytokines like IL-25 (also called IL-17E), TSLP and IL-33, 
released by multiple cells. Epithelial and mast cells can produce both IL-25 and IL-33, with 
eosinophils being IL-25 producers and fibroblasts, dendritic cells, macrophages, osteoblasts 
and endothelial cells being IL-33 producers.  Basophils also release IL-4, which plays a role 
in maintaining ILC2 proliferation, and can activate ILC2 responses during cutaneous 
inflammation 60.  
Activation of ILC2 by these cytokines causes a type 2 reaction by ILC2s, which in turn 
change the physiology of nearby cells. IL-4 and IL-13 are known to induce muscle 
contraction 61, needed in the event of a parasite infection. IL-13 also triggers tissue repair, 
both directly, by affecting the collagen production and deposition, and indirectly, by elevating 
mucus secretion by goblet cells, or promoting TGF-β mediated repair 62. Moreover, during 
allergic lung inflammation, IL-13 is known to be responsible for inducing CD40+ dendritic 
cell to migrate towards the lymph nodes, where they can present antigens to naïve T cells and 
initiate an adaptive reaction, consisting in Th2 cell differentiation 63.  
IL-5 recruits and activates eosinophils, which attach to the surface of parasites 64 and release 
molecules toxic to the worm 65. AREG is also expressed by ILC2 under IL-33 exposure 57,56. 
AREG has important roles in the homeostasis of inflamed tissues and on the integrity of the 
epithelium under inflammatory conditions 66,67, through its capacity to activate macrophages 
(M2) that can limit acute inflammation and promote tissue repair through Arginase and IGF-
1, an epithelial mitogen 68.  
In mice two subgroups of ILC2 have been described. Steady state or natural ILC2s (nILC2), 
which reside in the lung and respond to IL-33, and inflammatory ILC2s (iILC2), that respond 
to IL-25 (but not IL-33) in multiple tissues, such as lung, spleen and liver. iILC2s are also 
detected in circulation, and are found in tissues upon inflammation69, and, like nILC2s, they 
were found to clear Nippostrongylus brasiliensis parasite infection via IL-13, and protect 
against Candida albicans fungus infection via IL-17.  
In human, so far there has not been any reports of iILC2-like cells, although it has been 






1.1.3 ILC3 and LTi cells 
In the late 2000’s, a series of reports, first in mice 72,23 and then in humans 73 showed how NK 
cell receptor positive innate lymphocytes were able to produce IL-22, naming this particular 
subset NK22. Later studies were able to distinguish them from NK cells, changing the 
nomenclature to group 3 ILCs 29. ILC3 are dependent on the RAR-RORγt transcription 
factor, maintained by IL-2 and IL-7 cytokines and are activated by IL-1β, and IL-23. 
Activation leads to the production of IL-22, IL-17A, IL-17F and granulocyte macrophage 
colony-stimulating factor (GM-CSF).  
In an inflammatory context, activated dendritic cells and macrophages are known to release 
IL-1β and IL-23. The combination of these two cytokines has been shown to work 
particularly well in terms of IL-22 release by ILC3s 73,74. IL-22 is known to enhance tissue 
repair and promote barrier immunity by decreasing bacterial threat. It aids host defense 
against extracellular pathogens by increasing the proliferation of epithelial cells, to strengthen 
the epithelial barrier upon pathogen attack. In collaboration with IL-17, it promotes 
production of defensins that have antimicrobial functions 75, and enhances goblet cells mucus 
production for extra barrier protection 76. In mice, IL-22 was shown to be effective in clearing 
the C.  rodentium pathogen 77 while ILC3 produced IL-17 provided protection following 
Candida albicans infection 78.  
So far, ILC3 represent the most diverse ILC subset. In mice, they can be subdivided into 
NKp46+ and NKp46- subsets, while in humans the same subsets are distinguished by the 
presence or absence of NKp44 79. NKp44+ ILC3s are known to produce the most IL-22 and 
are also marked by the expression of Helios (encoded by IKZF2), a member of the Ikaros 
family of transcription factors. NKp44- are the predominant IL-17 producers, and in a recent 
study they were shown to include ILC progenitors (ILCp), able to extravasate from the 
circulation, home to tissues and start differentiating into different ILC groups 80. Moreover, a 
study looking at single cell RNA transcripts in human ILC has revealed additional 
heterogeneity 6. It shows the presence of an ILC3 subgroup with antigen presenting 
capabilities expressing HLA-DR and HLA-DP transcripts, and a subgroup expressing CD62L 
and CD45RA, both markers of naivety, matching the phenotype of the aforementioned ILCp 
6.  
Another subset that also expresses RORγt and releases IL-22 is lymphoid tissue inducer cells 
(LTi), however, at least in mice, they develop from a progenitor distinct from the ILCp, thus, 
they are regarded as a distinct ILC subset 27,17. They were first discovered in the late 90’s and 
named after their function in organogenesis of secondary lymphoid structures 22. They play a 
role during embryogenesis through the release of TNF-α and lymphotoxin-β 81. Recently, 
neuropilin-1 (encoded by NRP1, also known as CD304 or BDCA4) was found on human 
cells with LTi function 82, and also in the transcripts of LTi cells isolated from mouse 83, 






1.2 DEVELOPMENT OF HUMAN INNATE LYMPHOID CELLS 
Extensive studies have been performed in the recent years in order to understand the origin of 
innate lymphoid cells, especially in mice. ILCs originate from the common lymphoid 
progenitor (CLP), found in the bone marrow. Expression of multiple transcription factors, 
like the nuclear factor, IL-3 regulated (NFIL3) 84, the thymocyte selection associated high 
mobility group box (TOX) 85, the inhibitor of DNA binding 2 (ID2) 86, T-cell factor 1 (TCF1) 
87 and the ETS proto-Oncogene 1 (ETS1) 88, lead to the formation of the common innate 
lymphoid progenitor (CILP). NK cell precursors (NKp) can differentiate from the CILP to 
give rise to NK cells, through the action of T-bet and eomesodermin 89.  
Thanks to GATA binding protein 3 (GATA3) expression, the CILP develops into the 
common helper innate lymphoid progenitor (CHILP) 90, which is capable of differentiating 
into either the aforementioned ILCp (via zinc finger protein PLZF expression 91) 28 or the LTI 
progenitor (LTIp). LTi cells need RORγt, TOX and ID2 to transition into their mature form, 
to then perform their organogenesis function. 
In humans, the intermediate cellular stages of ILC development are not yet defined 
completely. A RORγt+CD34+ hematopoietic progenitor cell found in tonsils and the intestinal 
lamina propria has been linked to ILC3 development but not NK cell development 92, while a 
similar population of CD34+CD45RA+CD117+ found in secondary lymphoid tissues was 
shown to be capable of maturing into all ILC subsets including NK cells 93, thus sharing more 
similarities with the CHILP. A recent study also showed how CD117+ ILCs found in the 
blood harbor ILCp derived from hematopoietic stem cells, and that they can migrate to tissues 
to generate all ILC subsets, including NK cells (Figure 2) 80. These studies underline the 
possible difference between human and mouse ILC biology, since in mice it is currently 
believed that ILCs are tissue-resident cells generated from local precursors 94. More studies 
are needed in order to further elucidate developmental stages, migration and tissue residency 




Figure 2. Model for differentiation, tissue distribution and migration of ILCp. HSC: hematopoetic 
stem cells. ILCp: ILC precursors. (Top) CD34+ HSC and CD34+ ILCp are present in fetal liver and 
other secondary lymphoid organs. These cells mature into CD34- multi-potent ILCp that migrate to 
the peripheral blood to then seed tissues and mature into ILC. (Bottom) CD34+ HSC give rise to 
multipotent ILCp directly or through a CD34+RORytdim intermediate step. Reproduced from Mjösberg 
J., Mazzurana L. Immunity. 2018 
 
1.3 PLASTICITY IN INNATE LYMPHOID CELLS 
Human ILCs are naturally very plastic; they have the capacity to change their phenotype and 
function upon cytokine stimulus, thereby adapting to environmental stimuli. In this section I 
will give an overview of such trans-differentiation capacity. Figure 3 gives a graphical 
overview of the plastic combinations ILC can achieve.   
ILC1-ILC3 plasticity 
In the context of inflammatory bowel disease (IBD), tissues in the gut can be extremely 
inflamed, to the point that surgery is the only possible solution to make the patient feel better, 
by removing inflamed sections of the intestine. In this highly inflamed environment, studies 
have shown that the ILC frequencies do not change, but the proportion of ILC1 in the lamina 
propria of Crohn’s disease patients does, increasing substantially 30. In such an environment, 
CD14+ DCs are found to be releasing high amounts of IL-12, which binds to cells expressing 
IL-12 receptors, including ILC3. When stimulated with IL-12, ILC3 are found to 
downregulate their RORγt expression and to upregulate T-bet expression, the TF expressed 
mainly by type 1 cytokine producer cells. They also activate the cellular machinery necessary 
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for IFN-γ production. In culture, it has been shown that after 4 days of ILC3 stimulation with 
IL-12, the cells change their phenotype, losing CD117 and NKp44, and taking on an ILC1 (or 
ex-ILC3-like) phenotype 95. In vitro, this process is reversible by stimulating “ex-ILC3s” with 
cytokines promoting RORγt expression, like IL-23 and IL-1β. This increases RORγt 
expression while decreasing T-bet, and re-activates IL-22 production, while shutting down 
IFN-γ release. This also works on freshly isolated ILC1 95.  
We explored the transcriptional mechanisms underpinning ILC3-ILC1 plasticity in Paper I, 
with tonsillar ILC3 transdifferentiating towards ILC1-like cells under IL-12 IL-1β stimulus in 
vitro.  
ILC2-ILC1 plasticity 
As is the case with ILC3-ILC1 differentiation, ILC2-ILC1 differentiation also occurs in an 
inflammatory environment. Inflamed lung provides the right environment for this, especially 
in the case of chronic obstructive pulmonary disease (COPD), a condition characterized by 
chronic inflammation 96. ILC2 stimulated with IL-12 and IL-1β upregulate T-bet and become 
CD117- and lose CRTH2, acquiring an ILC1 (or “ex-ILC2”) phenotype 97,98,99. 
A recent study showed how IL-1β primes ILC2 for this process, mainly by increasing the 
expression of IL-12 receptor (IL12RB2). Changing the chromatin landscape also opens the 
locus required for IFN-γ transcription 100. IL-4 is shown to halt or reverse this effect, 
differentiating the ”ex-ILC2” to the original ILC2 phenotype 97.  
ILC2-ILC3 plasticity 
In human, recent studies report the transdifferentiation of nasal polyp ILC2 into IL-17 
producing ILC3-like cells. This process is triggered when cells are under the influence of 
TGF-β, IL-23 and IL-1β stimuli, cytokines released in the microenvironment upon 
microbacteria infection, like Staphylococcus Aureus and Pseudonomas aeruginosa. This 
plastic behavior of ILC2 explains the accumulation of ILC3 in the nasal polyps of patient 
suffering from cystic fibrosis 70. 
In mice studies showing how iILC2 found in lungs and expressing intermediate amounts of 
RORγt can lose IL-13 production and adopt IL-17 producing capabilities upon C.albicans 
infection, or stimulated in vitro by a IL-2, IL-7, IL-1β, IL-23 and TGF-β cocktail. 69 
NK cell-ILC1 plasticity 
Recent studies on mice have explored the possibility of NK cell differentiation to ILC1. It 
was shown that both in vivo and in vitro NK cells could differentiate into an ILC1-like 
phenotype by TGF- β stimulus 101. This pathway is controlled by SMAD4, a signal transducer 
that facilitates signaling pathway of TGF- β family cytokines. NK cells lacking SMAD4 lost 
their ability to produce cytotoxic molecules, thus losing their tumor killing capabilities 102. 






In human, one report described the ability of tonsillar ILC3 to transdifferentiate into NK cells. 
This transition is promoted by IL-12 and IL-15 stimuli, and triggers CD94, Eomes and T-bet 
upregulation. Cytokine release is also triggered, with TNF-α, IFN-γ, granzymes and perforin 
release, efficiently being able to target and kill K-562 cell lines 103. This report was in part 
confirmed by results in Paper I, with NK cell like phenotype obtained upon IL-12 and IL-1β 
driven transdifferantiation of ILC3 towards ILC1/NK-like cellular status.  
 
 
Figure 3. A graphical overview of human ILC plasticity and interaction with other cells. MZ: 
marginal zone; DC: dendritic cell; Human ILC respond to a variety of cytokines in their 
microenvironment released by neighboring cells, which trigger ILC trans-differentiation. ILC can 
interact with several other cell types influencing their phenotype and function. Reproduced from 







































2 INFLAMMATORY BOWEL DISEASE 
Inflammatory bowel disease (IBD) is a complex disorder resulting from the interaction of 
genetic and environmental factors, priming the gut immune response to malfunction 105. In 
Paper I we studied intestinal biopsies from IBD patients, while in Paper II we analyzed a 
large cohort of blood samples from IBD patients and compared cell type frequencies to 
samples from healthy blood. Here, I describe the pathogenesis of this disease and depict what 
role ILC play in IBD. 
What characterizes IBD is a chronic inflammation of areas of the gastrointestinal (GI) tract, 
and can manifest itself as Ulcerative Colitis (UC) or Crohn’s disease (CD). A non-patchy 
inflammation limited to the large intestine, the colon and the rectum, characterizes UC. The 
inflammation in UC tends to affect the mucosal and sub mucosa layers of the colon, rich in 
lymphocytes. A patchy inflammation, that may affect any part of the GI tract, and even extra-
intestinal sites, characterizes CD. In Paper II, the majority of the CD cohort exhibited 
ileocolonic inflammation, with the rest of the cohort having inflammation restricted to either 
the ileum or the colon. In contrast to UC, the inflammation in CD can be so severe as to be 
transmural, affecting all layers of the GI wall 105. The impaired barrier function leads to a 
translocation of commensal bacteria from the lumen to the submucosa, exacerbating 
inflammation 106. This inflammation is caused by the influx of activated cytokine-producing 
macrophages and neutrophils to the area, together with eicosanoids, free radicals and 
proteolytic enzymes 107, leading to the common symptoms of IBD, namely abdominal pain, 
rectal blood loss, diarrhea and weight loss 107,108. Regulatory mechanisms to contain this acute 
immune response fail to function properly, aggravating the state from acute to chronic. 
Another common characteristic of IBD is its relapsing-remitting course, especially in young 
adults, contributing heavily to the reduction in the quality of life of individuals affected by it 
109,110. 
The cause for IBD has been linked to a variety of factors, one of which is genetics. Genome-
wide associated studies (GWAS) have analyzed the genetic information of large IBD cohorts 
and compared that to the one of healthy cohorts 111,112,113,114,115. Many differences in genomic 
composition have thus been linked to this disease, with several publications connecting the in 
silico results from GWAS to mechanistical confirmation in vivo or in vitro 116,117.  
Environmental factors are another quite broad feature that has been linked to IBD 118. For 
CD, factors like cigarette smoking 119,120, having had an appendectomy 121, dietary animal 
protein 122, NSAID 123 or antibiotic use 124, psychosocial stress 125, depression 126 and oral 
contraceptive use 127, have all been associated with an increased risk of contracting this 
disease. Dietary fiber 128 and Vitamin D 129 have been connected with a decreased risk. For 
UC, consumption of dietary arachidonic 130 and linoleic acid 131, NSAID use 123, psychosocial 
stress132, depression 126 and postmenopausal hormone use 133, have been linked with a higher 
risk, while cigarette smoking 134 and early appendectomy (before the age of 20) 135 have both 
curiously been associated with a decreased risk. 
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As the immune system is directly or indirectly affected by both genetics and environmental 
factors, it is only logical to assume that the composition and function of immune cells is 
altered during IBD, as I will discuss in the next section, which focuses on ILC. 
 
2.1 INNATE LYMPHOID CELLS IN IBD  
As innate cells represent the first line of defense when the host is attacked, they play an 
important role in managing the invading pathogen, by sensing microbial antigens and 
organizing a first response through cytokine release. Antigen presenting cells later present the 
processed microbial antigen to the adaptive immune cells, which take over the immune 
response. In IBD, commensal bacteria leak to the submucosa, effectively initiating an 
immune response.  
Several reports have shown NK cells to be present at higher frequencies in IBD patients in 
the colonic lamina propria compared to controls 136,137. NK cells are known to produce IFN-γ 
when activated, a cytokine very efficient at recruiting macrophages (IFN-γ was originally 
called macrophage-activating factor), increasing their antimicrobial mechanisms and antigen 
presentation 138. Upon IFN-γ activation macrophages release IL-12, priming naïve CD4+ T 
cells for differentiation to one of their activated states, Th1 cells, which are in turn capable of 
releasing ulterior IFN-γ 139,140. This vicious circle is exacerbated by the maturation of 
dendritic cells, also releasing IL-12 to assist Th1 trans-differentiation 141.  
As mentioned in the chapter section about ILC plasticity, another innate lymphoid cell that is 
affected by IL-12 is ILC3. In humans, ILC3 are broadly divided into NKp44- and NKp44+, 
with the negative subgroup being more naïve and the positive subgroup being IL-22 
producers, and the major ILC3 subgroup present in a healthy intestine 142. In IBD, NKp44+ 
ILC3 have been found to trans-differentiate into an ILC1-like status, gaining the ability to 
secrete IFN-γ 95. Validating this finding, IBD disease severity has been shown to be 
associated with an increased presence of ILC1 143. Two ILC1 subgroups have been found to 
be enriched in the inflamed intestine, one restricted to the lamina propria 30 and one enriched 
in the epithelial tissue (ieILC1) 35. What distinguishes them is the presence of CD103 on 
ieILC1, which also lack CD127, with the latter marker present in lamina propria ILC1. 
ieILC1 are more similar to NK cells given the presence of CD94 and intracellular expression 
of EOMES, a transcription factor found in high amounts in NK cells. Moreover, ieILC1 
release granzymes and perforin 35. Both subgroups produce IFN-γ when activated. As IBD is 
characterized by a chronic immune response, the presence of an protracted elevated 
concentration of IFN-γ in the intestine, originating from ILC1, trans-differentiated NKp44+ 
ILC, CD4+ Th1 and NK cells, was found to negatively affect the intercellular tight junctions 
between intestinal epithelial cells, damaging the function of the epithelial barrier and 
effectively paving the path for pathogens to invade 144,145. 
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The role ILC2 have in IBD is unclear. There are a couple of studies showing their enrichment 
among both CD patients 146, and UC patients 142, although at very small frequencies. Thanks 
to their ability to release IL-5 and IL-13, they are very efficient at clearing helminth 
infections and mediate allergic asthma. As they also respond to IL-33 with amphiregulin 
(AREG) production, a mouse study showed how ILC2 can have a tissue-protective role in the 
intestine 147. The cytokine IL-25 also activates them, triggering an IL-13 response thought to 
elicit goblet and tuft cells regeneration after an helminth infection in mouse 148. Given the 
very small number of ILC2 found in inflamed IBD samples in human, it is difficult to 
pinpoint and describe their role and if the same mechanisms are as valid as in the mouse 
model. 
All in all, ILC play an important role in the pathogenesis of IBD, especially due to their IFN-γ 
production capabilities in an inflamed environment. As they can sense and respond to 
cytokines in the environment they should be taken into consideration when developing novel 

















































The work included in this thesis aimed to gain insight into several aspects of ILC biology in 
homeostasis, an in vitro inflammatory environment and in disease.  
Specifically, the three different studies aimed to: 
• Paper I: Determine the involvement of the transcription factor Aiolos (encoded by 
IKZF3) in ILC3/1 transdifferentiation, and to assess its role in ILC1 function through 
gene silencing. 
• Paper II: Analyze peripheral ILC disturbance in a cohort of IBD samples compared 
to samples at homeostasis, focusing on proteins encoded by IBD risk genes as 
assessed in published GWAS. 
• Paper III: Transcriptionally profile ILCs using single-cell RNA sequencing via 
Smart-seq2 technology, in order to delineate heterogeneity, identify potential marker 
proteins for ILCs and compare transcriptional profiles between peripheral blood, 















































4 METHODOLOGICAL CONSIDERATIONS 
A variety of techniques have been used during my research, both in vitro, ex vivo and in 
silico. Here I will focus on flow cytometry, the technological backbone to all papers included 
in this thesis, and gene expression analysis by single cell RNA sequencing, a key technology 
used in Paper III. Moreover, as all methods and technologies were applied to precious 
human samples, I will discuss sample collection as well as ethical considerations. 
 
4.1  ETHICAL CONSIDERATIONS 
All studies included in this thesis used human material as the primary data source. All studies 
were performed in accordance with ethical guidelines described in the Declaration of 
Helsinki. Informed consent was obtained for all studies, from either the patients directly or 
from legal guardians in the case of children prior to obtaining the sample. Relevant clinical 
information, i.e. gender, age, medical history, was shared with the researcher in order for 
more specific data analysis to be performed. 
For Paper I, we received tonsils, blood and gut biopsies. The tonsils were obtained from 
patients who suffered from obstructive sleep apnea. We receive the tonsils after the 
tonsillectomy. Hence, removal of tonsils was part of the clinical procedure and did not 
impose any further intervention for the patient.  
The most ethically delicate tissue used were gut biopsies, also in Paper I and Paper III. 
They were retrieved from patients undergoing colonoscopy, consequently prolonging the 
procedure since doctors needed to first collect biopsies for clinical matters, and then collect 
tissues for research, thus lengthening the colonoscopy procedure by several minutes. Also, 
before performing the colonoscopy, blood was obtained from the patients for clinical matters 
and research. This process was regarded as safe and of little pain to the patients.  
In Paper III lung tissue was collected from patients undergoing surgical lung resection, 
mainly due to cancer. Non-affected tissue was used for the project. No extra tissue was 
surgically removed in order to accommodate our study requirements; hence participation in 
the study did not entail further intervention.  
The additional risks endured by the patient is considered reasonable and justifiable by the 
gain of new research being performed on their specific diseases, hopefully leading to novel 
and more efficient medications and treatments. 
The studies included in this thesis were approved by the respective regional ethic committees 
as per the following permit number: Dnr 2016/1415-32, Dnr 2017/2404-32, Dnr 2017/1659-
32, Dnr 2016/128-32 (Paper I and III), Dnr 2018/1819-31/1 (Paper III) and Dnr 2010/313 
(Paper II).  
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4.2  FLOW CYTOMETRY 
As the name of this particular method suggests (cyto = cell, metry = measurement), a flow 
cytometer measures single cells in a fluidic system. The basic principle consists in pointing a 
laser beam to the flowing stream of cells, and through the help of strategically placed 
detectors, disturbances in the beam of light are measured when each cell passes through the 
beam, giving information about the cell’s size and granularity. This basic information can 
already give the immunologist an idea of what kind of cells are being analyzed, given that 
lymphocytes, monocytes and neutrophils are easily distinguishable by size and granularity.  
Modern cytometers are able to gather multiple data points on each cell, by being equipped 
with special detectors measuring fluorescence. Fluorescent compounds within or on top of a 
cell’s membrane can be excited when hit by a laser beam, emitting light that can be measured 
by the detectors. There are a wide variety of commercially available fluorochromes that are 
conjugated to antibodies specific to a surface antigen or intracellular proteins. The only 
limitation to how many different fluorochromes can be used in one experiment is the number 
of laser excitation sources available in the cytometer. The main cytometers used to gather the 
data presented in this thesis were equipped with four lasers (blue, red, yellow-green and UV), 
enabling detection of up to 18 colors. 
In addition to the capabilities of flow cytometers to gather data on the size, granularity, 
presence or absence of a protein and its level of expression, fluorescence-activated cell 
sorting (FACS) offers the ability to sort live cells into a specific tube or the well of a plate 
based on the cytometry data. FACS enables the researcher to isolate a specific cell of interest 
from a sample, without harming the cell. The use of FACS technology is key in ILC research, 
as ILC are a rare lymphocyte population that often needs enrichment in order for the 
researcher to generate meaningful data. FACS was used to isolate ILC mainly from tonsils in 
Paper I, while in Paper III a considerable effort was made to set up ILC single cell sorting 
in 384 well plates from a variety of tissues. 
Data acquired from flow cytometers was analyzed with the FlowJo version 9 or 10 software 
and SPICE version 5 or 6. Unbiased analysis (i.e. not gate-based) was done through R 
software (various versions), with stochastic neighbor embedding analysis (SNE) or uniform 
manifold approximation and projection (UMAP) methodology being implemented in order to 
reduce the multidimensionality of the data 149.  
 
4.3  GENE EXPRESSION ANALYSIS 
During the past two decades, the way researchers approached gene expression analysis has 
varied substantially. In Paper I, we used one of the earlier methods to assess gene expression 
differences, namely microarrays. This technology is based on the hybridization of synthetic 
oligo probes to target strands of cDNA, resulting in fluoroscence. By scanning the chip using 
high-throughput screening, the fluorescence is quantified, giving the researcher reliable data 
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on the levels of gene expression of the sample analyzed. Although microarrays are relatively 
inexpensive and very successful in analyzing large amounts of biological samples in a limited 
amount of time, they also come with limitations. These limitations vary, from high 
background levels due to cross-hybridization 150, to reliance of existing knowledge about the 
genome sequence. In order to overcome such limitations, RNA sequencing was developed.  
RNA sequencing (RNA-Seq) is a method using next-generation sequencing (NGS) 
technology to measure the presence and the amount of RNA transcripts of a biological 
sample at a given time. It is a powerful method that replaced microarray analysis in the mid-
late ‘00s, as it made it possible to fully sequence the whole transcriptome while microarrays 
only offered limited profiling of pre-defined transcripts 151. RNA-seq measures the average 
expression level of each gene across a large population of cells, giving the researcher a great 
tool for comparative transcriptomics (when analyzing samples from the same tissue, or a 
specific type of cell, in different species). The single-base resolution of this method is a big 
leap from the microarray standard, which had a resolution limited by the size of the probes in 
the chip, ranging from several base pairs to 100 base pairs. 152. Additionally, RNA-seq does 
not have an upper limit when it comes to the quantification of gene expression level, which is 
simply equal to the number of transcripts present in the sample for a specific gene. This 
quantification ranges from a few transcripts up to thousand-folds. The high dynamic range is 
far more sensitive than microarrays, which have ranges spanning from one-hundredfold to a 
few hundredfold, making it hard for microarrays to detect genes that have a very low or very 
high expression 152.  
A significant drawback of RNA-seq is its inability to provide insights into the heterogenous 
nature of gene expression. In other words, it does not tell the researcher the level of gene 
expression of every cell, since that can be differentially expressed within the pool of cells 
used as input for RNA-seq, but only shows the average level of expression of such pool. This 
is important information for a researcher who wants to analyze the heterogeneity of a system, 
like in the case of developmental studies. In order to overcome these limitations, a method 
taking into account not pools of cells but single cells was needed.  
In the ‘90s, a number of techniques that analyzed gene expression levels in single cells were 
invented, such as fluorescent reporter constructs 153, single molecule RNA FISH 154, and later 
quantitative PCR 155. Although these techniques lead to important discoveries, they were very 
low-throughput, analyzed a small number of single cells and a limited number of genes. In 
2009, Tang et al developed the first method that allowed to perform RNA-seq on single cells 
156, paving the path for the single cell sequencing revolution still ongoing today.  
 
4.3.1 Single cell sequencing – Smart-Seq 2 technology 
During the last 13 years, single cell throughput has increased substantially (Figure 4). In the 
first single cell RNA study, Tang et al picked each cell under a microscope before lysing it 
and performing the downstream protocol. The manual process of picking single cells by 
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micropipettes required incredible work, and the data obtained by a few single cells was quite 
limited. This limitation slowed the widespread use of this technology considerably. New 
methods increasing the throughput were developed in 2011, when multiplexing was 
introduced by the Linnarson lab 157. It brought the number of single cells analyzed to close to 
100, but in 2013 158 and later in 2014 159 the use of integrated fluidic circuits and liquid 
handling robotics made it even easier to capture single cells, triggering an extensive use of 
scRNA analysis within immunological research. In Paper III, through FACS sorting, we 
were able to isolate thousands of cells. Nowadays, the uprise of automated capture systems in 
nanoliter-sized aqueous droplets 160, picoliter chambers 161 or microwells have brought the 
reagent volumes and labour intensity to an even lower threshold, while raising the throughput 
to the tens of thousands of cells.   
The majority of scRNA-seq library preparation protocols share a general workflow, although 
the chemistry used has changed throughout the years (Figure 4). In broad terms, after cell 
isolation with one of the methods discussed above, the cell is lysed, its mRNA is reverse 
transcribed, tagged with a barcode or cell identifier, and the cDNA of all the cells is then 
pooled, amplified and finally sequenced.  
 
 
Figure 4. A: Depiction of several isolation methods for single cell retrieval in a chronological order. 
B: Timeline showing the progress and improvement in number of single cells isolated in studies 
ranging from 2009 to 2017. The main chemistry protocols used in the most important published 
studies are overlaid on the timeline. Adapted by permission from Macmillan Publishers Ltd: Springer 
Nature, Nature Protocols, Svensson v. et al., copyright 2018. 162 
In Paper III, our collaborators used Smart-seq2 methodology to prepare libraries, which 
allowed full-length transcriptome sequencing, something that is not possible in tag-based 
quantification scRNA library protocols. As the name suggests, full-length sequencing allows 
a uniform read coverage of the transcripts, while tag-based methods capture either the 3’ or 5’ 
end of the transcript. A recent publication comparing the six prominent scRNA library 
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preparation methods (CEL-seq2/C1 163, Drop-seq 160, MARS-seq 159, SCRB-seq 164, Smart-
seq/C1 165, Smart-seq2 166,167) , showed how Smart-Seq2 ranked highest in detected genes per 
cell (highest sensitivity), and had the highest accuracy of transcript level quantification  168.   
As our goal was to characterize a rare population of cells such as ILC, maximizing the gene 
detection rate was our primary interest. As Smart-Seq2 was key in achieving that goal, a brief 
description of the protocol is shown in Figure 5. Briefly, the isolated cells are lysed in a 
buffer containing dNTP and oligo DT primers with a known anchor sequence at their 5’ end, 
which prime reverse transcription of the first strand. For the second strand synthesis, template 
switching is performed, which requires the terminal transferase activity of Moloney murine 
leukemia virus  (MMLV) reverse transcriptase. MMLV transcriptase adds several cytosines 
to the 3’ end of the first strand to act as a binding partner to the template-switching oligos 
(TSO) containing a locked nucleic acid (LNA; improves the thermal stability of the TSO), 
that effectively primes the synthesis of the second strand of cDNA. After reverse 
transcription, all cDNA strands share the same universal anchor sequence (ISPCR) and can 
undergo PCR amplification. For conversion into sequencing libraries, the amplicons are 
simultaneously fragmented by Tn5 transposase, and tagged with adaptor sequences that are 
then used as binding sites for the concluding enrichment PCR. The final libraries can then be 
pooled and sequenced 166. 
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Figure 5. Outline of the Smart-seq2 protocol and the corresponding procedure steps. Adapted by 
permission from Macmillan Publishers Ltd: Springer Nature, Nature Protocols, Full-length RNA-seq 









5 RESULTS AND DISCUSSION 
5.1  PAPER I - AIOLOS AND IKAROS AND THEIR ROLE IN ILC3 TO ILC1/NK 
TRANSDIFFERENTIATION 
The work presented in Paper I stems from a study previously published by our group 6, 
which focused on unraveling heterogeneity of human tonsil ILC by scRNA-seq. One 
transcript that caught our attention was a transcription factor from the Ikaros transcription 
factor family, called Aiolos, encoded by IKZF3.  
The Ikaros family of transcription factors 
The Ikaros family of transcription factors was discovered throughout the ‘90s by a greek 
researcher, who named these zinc finger DNA binding proteins after characters from greek 
mythology. They function as key regulators of lymphocyte specification, expressed in HSC at 
an early developmental stage 169. The family is composed of five members, Ikaros (encoded 
by IKZF1), Helios (encoded by IKZF2), Aiolos (encoded by IKZF3), Eos (encoded by 
IKZF4) and Pegasus (encoded by IKZF5). Ikaros is a transcriptional regulator that controls 
differentiation into the T cell lineage and B cell lineage 170. Mice homozygous for the 
deletion of the Ikaros DNA-binding domain lack CLP, and consequently T, B and NK 
cells171. Aiolos was identified as a homolog of Ikaros, expressed in committed lymphoid 
progenitors, and its expression increases throughout T and B cell development 172. More 
recently Aiolos has been linked to Th17 cell differentiation and regulation of NK cell 
maturation 173,174. Ikaros and Aiolos interact with each other via heterodimerization. Another 
factor that can heterodimerize with both Aiolos and Ikaros is Helios, which is detected in the 
earliest hematopoietic sites of the embryo, in adult HSC and is later present in specific T cell 
subsets 175. Helios has also been linked to regulatory T cell differentiation 176,177. The Helios 
protein shows a high degree of conservation to the Ikaros protein (73% overall similarity) and 
the Aiolos protein (67% similarity) 175. Eos is most highly related to Helios, and it is involved 
in osteoclast differentiation and muscle development 178,179. Pegasus is the newest members 
of the family and limited research has been done to understand its function. 180.  
As shown in figure 6, Ikaros is expressed more or less homogeneously by all human tonsil 
ILC, while Helios is mostly found on ILC3. What caught our attention was the high 
expression of Aiolos in tonsil ILC1. As ILC1 lack a marker that defines them, and TBX21 
(encoding for T-bet) transcripts in tonsils were found to be very low in ILC1 by scRNA-seq 
analysis, the Aiolos transcription factor seemed like the perfect candidate for a more in-depth 
analysis.   
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Figure 6. Ikaros family transcripts expression in human tonsil ILC. Violin plots show expression 
distribution across ILC subgroups. Adapted from Mazzurana et al. EJI 2019. 
We validated the sequencing findings on blood and tonsil tissues on a protein level. Efforts 
were focused on Ikaros, Aiolos and Helios, as Eos and Pegasus showed a low homogeneous 
expression in ILC. We could confirm a high level of Ikaros expression by all ILC (NK cells 
included), expression of Helios in ILC3, with its highest expression in NKp44+ ILC3, and 
Aiolos expression in ILC1 and NK cells. Overall, the TF pattern of blood and tonsils were 
very similar to each other. 
As we targeted the analysis on ILC1, we co-stained T-bet and Eomes, two transcription 
factors known to be expressed in group 1 ILC, together with Aiolos. We could find a 
substantial amount of triple positive cells in our analysis of tonsil ILC1, even though every 
effort was done to exclude NK cell inclusion. The discovery of ILC1 expressing Eomes is in 
line with other reports showing Eomes+T-bet+ in blood, gut and liver ILC1 142,10. In the liver, 
the distinction between NK and ILC1 is even more challenging given the presence of a 
resident NK cell being Eomes-T-bet+, active in cytokine release and with a reduced cytotoxic 
capability 181. The only distinction for ILC1 is its KIR and CD49a expression and the lack of 
CD127 181. The hunt to characterize a bona fide ILC1 given their confusing TF profile has 
been a topic of debate 40,182,38,37. In Paper III we tried to answer this question by performing 
scRNA-seq and downstream unbiased analysis on a variety of tissues, where we could 
confirm the presence of an Eomes+ ILC1 population at steady state mainly in blood, but also 
in tonsil, colon and lung (Paper III, Figure 1E and S3). This population was separate and 
distinct to NK cells and Eomes- ILC1, which could possibly contain bona fide ILC1. 
In a disease state characterized by intestinal inflammation, ILC1 are known to increase in 
numbers, as shown in previous studies 30,95. In Paper I (Paper I, Figure 2) we confirmed this 
finding by analyzing samples from patients affected with IBD, that were highly enriched in 
ILC1 compared to non-IBD samples or samples from a non-affected area. Aiolos  was found 
to be expressed in ILC1 in both the inflamed and non inflamed samples. 
Interestingly, around 20% of tonsil ILC1 were comprised of either Aiolos single positives or 
Aiolos+ Tbet+Eomes-. Given Aiolos’ role in gene regulation, we set out to learn more about 



































fragile nature in vitro, we performed a series of experiments on tonsil ILC3 to better 
understand Aiolos’ role in ILC3-ILC1 plasticity. 
Aiolos is upregulated during ILC3 to ILC1/NK trans-differentiation  
In Paper III, when examining ILC3 from tonsil tissue by scRNA-seq, we could distinguish 
two distinct clusters within tonsil ILC3 when analyzing the data through dimensionality 
reduction software (Paper III, Figure 1d, cluster 4 and 9). Through trajectory analysis we 
could categorize one subgroup as more activated, expressing transcripts such as NCR2, and 
the other cluster more naïve, expressing transcripts such as SELL, that we renamed ILC3a and 
ILC3b respectively. These findings were in line with previous reports on human NKp44+/- 
ILC3 183. 
In Paper I, using an in vitro system, we sorted and cultured tonsil ILC3 (comprising of 
ILC3a and ILC3b) and treated them with either IL-2 + IL-12 + IL-1β cytokine mix or IL-2 + 
IL-23 + IL-1β, artificially pushing the ILC3 towards an ILC1-like state or towards a more 
active ILC3 state respectively, as seen in Figure 7.    
  
  
Figure 7. Representative plot showing ILC trans-differentiation and consequent Aiolos expression 
after an in vitro 4 to 6 day culture and cytokine treatment. Adapted from Mazzurana et al. Eur J Imm. 
2019. 
Aiolos was highly upregulated in the IL-2 + IL-12 + IL-1β condition compared to the control 
(IL-2 stimulation) or IL-2 + IL-23 + IL-1β condition. Ikaros and Helios were also 
homogeneously upregulated, maintaining a high expression in all conditions. 
The cells generated by this culture were IFN-γ producers, and comprised of both ILC1 and 
NK cells, that we distinguished by the expression or lack thereof of the TF Eomes and the 
inhibitory NK protein NKG2A. Eomes- NKG2A- cells expressing Aiolos and/or T-bet, that 
also expressed CD161, fit with the phenotype of ILC1, while Eomes+ NKG2A+ and Eomes+ 
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The presence of NK-like cells after trans-differentiation culture was expected, given various 
reports of describing similar results. Raykova et al. used the cytokine mix IL-12 + IL-15 to 
trans-differentiate human ILC3 cells to NK cells or NK-like cells, both at the bulk and at the 
single cell level via cloning 103. Even though they did not use IL-1β, they did culture tonsil 
ILC3 in a system using irradiated allogenic lymphocytes (also called feeder cells) for 
expansion. This artificial system has been reported to provide a source of IL-1β, together with 
other cytokines such as IFN-γ, IL-12, TNF-α, IL-6, IL-8 and IL-13, providing an additional 
inflammatory stimulus to the culture 97. The NK cells produced in their culture displayed 
characteristics of early stage 4 NK cells, with the machinery necessary to produce and release 
cytotoxic molecules like granzymes and perforin 103. In Paper I, both NKp44- and NKp44+ 
ILC3 cultured with IL-2 IL-12 and IL-1B were capable of producing granzyme B and a small 
amount of perforin (data not shown).  
Hughes et al. describe how another developmental intermediary of NK cells, known as “stage 
3”, characterized by a phenotype of CD34-CD117+CD94-, could include ILC3 expressing 
IL1R1 and the aryl hydrocarbon receptor (AHR). AHR is a ligand-dependent transcription 
factor at the center of much research in the past decade 184,185,186. It has been linked to the 
mediation of gut ILC2-ILC3 balance in the murine gut 187, ILC3/ILC1 balance in the human 
ileum in CD patients 188, Th17 differentiation 189, and Treg development 190. By inhibiting 
AHR, they were able to differentiate IL1R1hi IL-22 producing ILC3 into CD94+Eomes+T-
bet+ cytolytic mature NK cells 191.  
Given that tonsil ILC3 in Paper I were sorted as Lineage-CD127+CD117+CD94-, it is 
possible that some of these immature NK developmental intermediaries found their way in 
the ILC3 gate, and under an inflammatory stimulus of IL-12 and IL-1β they developed into 
NK cells. Furthermore, KLRC1 transcripts (encoding for NKG2A) were found in steady state 
tonsil ILC3 in Paper III, although not expressed at the surface. It is possible that the same 
cells under trans-differentiating stimuli would translate that transcript into protein, equipping 
the cell with an inhibitory protein.    
Aiolos and Ikaros silencing decreases ILC3 to ILC1/NK transdifferentiation and increases 
ILC3 activity 
As both Aiolos and Ikaros were highly upregulated in the transdifferentiation culture, we 
sought out to determine how the silencing of these two TF would affect the phenotype and 
function of the cells in culture. For this purpose, we treated the cells with Lenalidomide. 
Lenalidomide is an immunomodulatory anticancer drug developed in the ‘90s. It is an 
analogue of Thalidomide, a drug that gained notoriety in the ‘60s after being used as a 
treatment of pregnancy related morning sickness, causing deformations in the fetus 192. 
Lenalidomide’s mode of action involves the selective targeting of both Aiolos and Ikaros for 
degradation, by triggering their ubiquitination via the CRBN-CRL4 ubiquitin ligase 193,194. It 
works particularly well in treating multiple myeloma (MM), where both Aiolos and Ikaros 
play an important role in the disease. Both TF are regulators of NK- κB and indirectly 
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downregulate the TF MYC and the interferon regulatory factor 4 (IRF4), causing a lower cell 
cycle in the tumor cell together with an increased apoptosis 195. 
Lenalidomide treatment of the ILC3 in culture under an IL-12 + IL-1β trans-differentiating 
stimulus significantly lowered Aiolos and Ikaros expression. T-bet followed in their path, 
suggesting that these three TFs might be co-regulated. A confirmation that T-bet and Aiolos 
cooperate in shutting down the ILC3 program was shown in a recent publication by Cella et 
al. via a chromatin analysis approach, where they described Aiolos and T-bet collaborating in 
the repression of regulatory elements such as IL-22 and RORγt active in ILC3. Moreover, our 
microarray on lenalidomide treated ILC3 cultures showed the upregulation of several ILC3 
transcripts, such as RORC, IL-22 and NRP1, going in the same direction as Cella et al.’s 
findings. Interestingly, Helios increased substantially, showing the inversely proportional 
nature between the three members of the Ikaros family, as was also seen in studies in mice, 
with IKZF3-/- mice expressing higher levels of IKZF2 transcript 174. 
As graphically summarized in Figure 8, in Paper I we could successfully sort and culture 
tonsil ILC3, trans-differentiate them into ILC1/NK cells capable of releasing copious 
amounts of IFN-γ. Upon lenalidomide treatment, Aiolos, Ikaros and T-bet TFs were 
downregulated. This process triggered the upregulation of RORC and Helios, significantly 
limiting the ILC3 to ILC1/NK cell trans-differentiation and increasing the proportion of IL-
22 releasing ILC3, following the decrease of the ILC1 program.  
As ILC trans-differentiation takes place in conditions such as IBD, characterized by high and 
chronic inflammation in tissues rich of ILC3, more research is needed in regard to targeting 
such cells with compounds sharing lenalidomide’s ability to downregulate key TFs, in order 
to limit trans-differentiation towards inflammatory cells and instead increase tissue protecting 
cytokines release such as IL-22.  
           
Figure 8. A graphical summary of the effect of Lenalidomide treatment to tonsil ILC3 undergoing 
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5.2  PAPER II - CIRCULATORY ILC IN IBD 
When it comes to ILC in IBD, for obvious reasons the intestinal tract has always been the 
organ of primary focus, as the condition manifests itself primarily in that site. Several studies 
looked at ILC to identify disturbances in their composition at mucosal sites, most often by 
looking at patient’s samples in the form of punch biopsies, obtained through endoscopic 
examinations, or resection material after surgical intervention. By focusing on the main organ 
of interest one leaves out how ILC in other tissues respond to the disorder, with only a few 
reports analyzing ILC in non-GI tissues, often lacking the power to reach statistical 
significance in their findings 142,196,197.  
In Paper II we set out to perform a thorough analysis of ILC in peripheral blood in a large 
Swedish cohort of peripheral blood samples composed of 53 CD patients and 43 UC patients. 
To understand IBD specific disturbances in ILC composition, we compared the results to a 
cohort of 45 age and sex-matched healthy blood donors (HC). 
Exploiting IBD GWAS studies for the selection of ILC-IBD-associated markers 
We adopted a flow cytometry approach to identify possible protein expression differences in 
the cohort. In order to do that, an ad-hoc panel was created with standard ILC markers and 
markers for proteins known to be associated with IBD. Given the limited number of channels 
available on the FACS machine (at the time limited to 16 colors), we adopted an approach 
consisting in matching GWAS IBD risk genes with markers known to be present in ILC (at 
least as transcripts).   
As briefly introduced in a previous chapter focusing on IBD, GWAS studies take genetic 
information of a very large cohort of patients, and compare that to the one of healthy controls. 
The goal of GWAS is to examine common genetic variants in the cohorts to find if any 
variants are associated with the disorder studied. The comparison of the genomes can lead to 
the discovery of single nucleotide polymorphism (SNP) associated with the disease of 
interest. Several GWAS studies analyzing data from IBD cohorts were successful in linking 
several genetic loci, dictated by interesting SNP locations, to the disease 111,112,113,114,115.  
In order to deduce which genes made the most sense to include in the final flow cytometry 
panel, we extrapolated all genes included in the 201 loci associated with IBD described in the 
two main GWAS studies on IBD 111,112. Each IBD risk-associated locus comprised of an 
average of seven genes per locus, with some loci encompassing only a few genes while some 
others including dozens of genes, given the linkage disequilibrium patterns in the human 
genome and the ~250kb span of each risk locus 198. The consequent list of 1502 risk genes 
was then compared to the 757 differentially expressed genes in ILC stemming from our study 
looking at tonsil ILC via scRNA sequencing technology 6. The resulting 83 matching genes 
were filtered through the Genotype-Tissue Expression project (GTeX) portal, a 
comprehensive public database that enables the researcher to study human tissue-specific 
gene expression and regulation and its relationship to genetic variations 199.  Through GTeX, 
we could filter the 83 candidate genes, with 20 of them resulting as residing in expression 
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quantitative trait loci (eQTL), meaning that the genetic variance in the IBD risk loci 
containing such genes can explain variation in gene expression level 200. The 20 genes in 
eQTL were then filtered for level of expression, by setting a threshold to the reads per 
kilobase of transcript per million mapped reads (RPKM) of tonsil ILC transcripts, although 
our cohort and GTeX analysis was based on blood. Finally, only a dozen genes survived all 
steps of this stringent filtering, with only a few having a reliable antibody available for 
purchase. After this intricate selection process (simplified in Figure 9), two genes made the 
cut: SLAMF1 and HLA-DR. 
   
Figure 9. Rationale behind the IBD-associated marker selection for the flow cytometry panel. 
Characterization of circulating ILC through multi-color flow cytometry  
A classic and well-established ILC gating strategy was used to investigate ILC frequencies, 
with all ILC being Lineage-CD127+, and further subdivided into CD117+ ILCp, CRTH2+ 
ILC2 and CD117-CRTH2- ILC1. Curiously, we could not find any differences in peripheral 
blood ILC frequencies between patients and control, as previously reported in similar studies 
142. In Paper I, we detected ILC1 enrichment in the inflamed gut biopsies of IBD patients, 
compared to controls, confirming previous reports 30,142. Hence, it seems that blood ILC 
frequencies are not affected by the condition, although a recent study by Creyns et al. 
detected higher circulating ILC1 and ILC2 frequencies, and a lower ILCp frequency on a 
similar sized cohort of IBD patients and healthy donors to the one presented here 197. The two 
cohorts are hard to compare given the patient’s treatment status, with Creyns et al. focusing 
on patients on biologics (Ustekinumab, anti-TNF and Vedulizumab), while ours having only 
the minority of patients on biologic agents. Moreover, the inflammatory status of the IBD 
cohorts might differ, as our cohort had a lower average disease activity level for the UC 
group, as reflected by the Mayo score, and possibly even in the CD group, although the 
activity indexes adopted in the two papers differ. 
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As CD is a disease characterized by systemic inflammation, we were successful in 
discovering a number of activation markers expressed in ILCp from CD patients compared to 
HC, namely CD56 and NKp44, with HLA-DR additionally being expressed in ILC1 and 
ILC2. The increased frequency of expression of CD56 and NKp44 proteins was correlated in 
the CD cohort, hinting to a possible co-regulation. CD56 is a neural cell adhesion molecule 
encoded by the NCAM1 gene, and is one of the hallmark proteins present on the surface of 
NK cells, mediating their cytotoxicity and denoting their level of maturity given its level of 
expression 201,41. HLA-DR, as shown in a recent study looking at human peripheral blood 
ILC, is upregulated during inflammation, being NF- kB dependent 202. NKp44, encoded by 
NCR2, is an activating protein found on NK cells, belonging to the natural cytotoxicity 
receptor (NCR) family. In tissue, ILC3 are known to have a heterogeneous expression of 
NKp44, as we show in Paper I (Paper I, Figure 3A - tonsil) and Paper III (Paper III, Figure 
3g – NCR2 transcripts in tonsil and gut ILC3 at steady state). In blood, at steady state there is 
no sign of NKp44 protein expression, as shown in the HC cohort (Paper II, Figure 2,4 and 
5B). Its upregulation in circulatory ILCp has been reported on a smaller CD cohort (with two 
of seven CD samples having and enrichment in NKp44+ ILCp) and in leukemia patients, 
where NKp44 expression was associated with a lower risk of graft-versus-host disease 
(GvHD) following hematopoietic stem cell transfer (HSCT) 203,196. Creyns et al. could detect 
an enrichment of NKp44+ ILCp in CD patients undergoing biologic treatments, especially in 
the anti-TNF treated subjects, and to a lesser extent in ustekinumab-treated subjects. In our 
cohort, none of the CD patients with an enriched circulating NKp44+ ILCp was treated with 
biologics. Interestingly, in both active and remission UC patients, this population of cells was 
absent (Paper II, Figure 3,4 and 5B), as also reported by Creyns et al., making this finding, 
within IBD, CD specific. As this population of cells has the ability to produce IL-22, a 
cytokine known for its tissue repairing qualities and surely useful in a CD context, it would 
be interesting to find out what triggers their enrichment in circulation of CD patients. More 
research on this topic is needed. 
Lim et al. recently described how blood CD117+CD45RA+ ILC represent a precursor 
population of ILC, that can then migrate to tissues and mature into their active form 80. Given 
these findings, the marker used to distinguish naïve ILCp in Paper II was CD45RA, and the 
difference in their frequency (CD45RA+ ILCp) was highest between CD and UC, as the UC 
cohort was mainly composed of patients in remission (36 patients with and average Mayo 
score of 0.6 ± 0.7) with only four in an active state (Mayo score 4 ± 0.8). With a higher level 
of activation in the CD samples, it was interesting, although somewhat expected, to see the 
frequency of naïve ILCp decrease, as it is most likely that ILCp matured into NKp44+/-CD56+ 
ILC3. To confirm the switch of naïve CD45RA+ ILCp, a negative correlation to activated 
subsets such as CD56+ ILC3 and ILC1 frequencies was described in CD patients (Paper II, 
Figure 3 and 5C).  
The IBD-associated marker SLAMF1, found to be present in the ILC2 compartment, had an 
increased expression within both CD and UC cohorts as compared to HC (Paper II, Figure 
2,4 and 5D). When correlating patient clinical information, it was observed that SLAMF1+ 
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ILC2 frequencies in CD patients with active disease were inversely correlated to HBI score 
(Paper II, Figure 6B). This correlation hints to a possible involvement of this population of 
cells with reduced disease activity among active CD patients. When compared to their 
SLAMF1- ILC2 counterpart, SLAMF1+ ILC2 expressed a higher amount of CRTH2 and 
CD161, with GATA3 being at the limit of significance (p= 0.056). In order to evaluate the 
activation level of the SLAMF1+ population, we stained for the activation markers CD25 and 
CD69, which were not differentially expressed when compared to SLAMF1- ILC2. Upon 
ILC2 activating cytokine stimulation, a mix of IL-2, IL-25, IL-33 and TSLP, we could detect 
IL-13 release from SLAMF1+ ILC2, although the level of release was similar to their 
counterpart SLAMF1- ILC2. In Paper III, the SLAMF1 transcript was found in ILC2 from 
blood, tonsil and lung tissue (Paper III, Figure 4b). Weighted correlation network analysis 
(WGCNA), used to find clusters of highly correlated genes, placed SLAMF1 in the same 
cluster as IL13, IL17RB, IL1RL1 and PPARG, suggesting a high degree of activation for the 
cells expressing it. Further research is needed to shed light on the role of this Slam family 
receptor in ILC, as it could serve as a potential therapeutic target in IBD, given its 
relationship with a mature and active ILC2 subpopulation of cells.  
Characterization of circulating ILC through dimensionality reduction 
Multi-color flow cytometry is a great tool to research immune cells, given its ability to detect 
multiple markers for each cell analyzed. The data produced with such technology is thus 
multi-dimensional, and analyzing it with a classical gating strategy can lead to inaccurate 
conclusions, since all gates set by the analyst are biased by personal judgment on how strict 
or loose a gate should be for each specific marker. Because of this issue, we adopted a 
dimensionality reduction approach to analyze the dataset, in order to verify that our results 
based on statistics on the frequency of cells from biased gating strategies were not flawed. 
Although this approach is not completely unbiased, since we selected Lineage-CD45+CD127+ 
cells by manual gating before feeding the data to the algorithm, it is unbiased when it comes 
to the downstream analysis of all markers of interest.  
The data was projected into lower-dimensional (2D) space, which made it easier to analyze 
and visualize. The non-linear dimensionality reduction technique called t-distributed 
stochastic neighbor embedding (t-SNE), a machine learning algorithm focusing on retaining 
the structure of neighbor points, was adopted 204. The use of a residual plot display readily 
portrayed differences between all combinations of CD/UC and HC cohorts. The differences 
in cell frequencies between cohorts were well represented in the t-SNE plots and kernel 
density based residual plots, confirming the statistical differences of cell frequencies taken 
from biased gating. 
In summary (Figure 10), in Paper II we analyzed a large cohort of IBD and HC blood 
samples via multi-color flow cytometry and downstream dimensionality reduction algorithm. 
We were able to identify cellular activation especially in the CD cohort, with an enrichment 
of CD56+ and NKp44+ ILCp and HLADR+ ILC1 and ILC2, compared to steady state 
frequencies in HC. SLAMF1, a marker selected associated with IBD as shown in GWAS, 
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was upregulated in ILC2 in IBD compared to HC. SLAMF1+ILC2 characterization showed 
increased cell maturation features compared to SLAMF1-ILC2, given the higher CRTH2, 
CD161 and GATA3 expression. More research is needed to explore the role of circulatory 
and resident SLAMF1+ILC2. 
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5.3  PAPER III - DISENTANGLING ILC HETEROGENEITY VIA SCRNA 
TECHNOLOGY 
Over the last five years, several publications adopted scRNA-seq technology to investigate 
the heterogeneity of human ILC in an unbiased way, although these efforts were limited to 
either a single specific subset of ILC 205, or to a specific single tissue 206,207,6. 
The work presented in Paper III focuses on exploiting the power of FACS, full length 
scRNA-seq, dimensionality reduction, correlation analysis and a tight collaboration with the 
clinics, to thoroughly investigate the cellular status of ILC in four different human tissues, 
blood, tonsil, lung and colon, at steady state. 
Well-established cell isolation protocols were adopted for blood, lung and colon tissues in 
order to maximize the number of cells retrieved and the quality of the RNA post cell lysis. 
Cells were sorted by FACS into 384-well plates according to surface marker definition of 
ILC/NK and CD4+ T cells, with surface marker expression level, identity and well placement 
of every cell recorded via index sorting (Paper III, Figure S1 – total of 4622 sorted cells). 
RNA quality was validated, with all plates later processed with smart-seq2 technology and 
sequenced by our collaborators. Upon retrieval of blood, lung and colon sequences, the tonsil 
data (648 cells) from Björklund, Forkel et al. was integrated to the dataset and a total of 5270 
cells were analyzed. 
Dimensionality reduction and clustering analysis reveals ILC tissue and subset 
transcriptional imprinting 
In contrast to the dimensionality reduction method adopted in Paper II (t-SNE), in Paper III 
we implemented unifold manifold approximation and projection (UMAP) to visualize our 
dataset in low dimensional space 208. Compared to similar methods, UMAP provides faster 
run times, scales well with larger datasets and produces a meaningful organization of cell 
clusters, preserving the local and global structure in the data 209. By labeling the resulting 
UMAP with tissue and celltype metadata from FACS, we were able to visually perceive the 
subset and tissue specific transcriptional imprinting of ILC (Paper III, Figure 1b-c). In order 
to identify distinct cell populations and cell states, we adopted the Louvain algorithm, as it 
was shown to scale well with large datasets 210. Louvain clustering is an unsupervised graph-
based method whose purpose is to find communities (i.e. clusters) of nodes (i.e. cells) with 
higher probability of being connected to each other than to members of other groups in the 
network. No matter the clustering method adopted, the process is not completely unbiased, 
since at least one parameter has to be set by the user. In our case, to optimize the clustering 
we set a modularity resolution parameter, which divided the quality controlled data (2956 
cells) into 20 different clusters (Paper III, Figure 1d). By comparing index data from FACS to 
each cluster, we observed a high agreement between protein FACS phenotype and the 
clusters subdivision (Paper III, Figure S3a), validating the resolution parameter set for the 
clustering step. Clusters were annotated based on known transcription profiles of human ILC 
17. We were able to distinguish single ILC1 and ILC2 clusters for blood, tonsil and lung 
tissues (annotated as B_ILC1, T_ILC1 and L_ILC1). No colon ILC1 or ILC2 clusters were 
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detected, as colon at steady state is known to have very little cells belonging to those 
subgroups of ILC 30,142. ILC3 cluster number varied, with tonsils and lung having two each 
(both clusters for tonsils and lung were initially merged and annotated as T_ILC3, and 
L_ILC3, respectively) and colon having four (initially merged and annotated as C_ILC3). A 
single cluster was identified for blood progenitors (annotated as B_nILC) and tonsil, lung and 
colon NK cells (annotated as T_NK, L_NK and C_NK). Two clusters with cells from 
multiple tissues were discovered, one reminiscent of ILC1 in all tissues, with EOMES 
transcription factor as shared transcript, placed in between ILC1 and NK cell cluster in the 
UMAP space (annotated as EOMES+ILC1), and a second cluster containing cells from tonsil, 
lung and colon, displaying a lower amount of total transcripts and naive properties, termed 
nILC (Figure 11). 
 
Figure 11. UMAP displaying clustered dataset, annotated clusters and number of features per cell 
(color intensity proportional to the cellular number of features). The number of features displayed for 
cluster 16/n_ILC are quite lower than for the rest of the clusters, given their naïve nature. 
Gene co-expression analysis identifies ILC transcriptional networks 
When trying to understand how a complicated machine engine works, does one try to count 
the bolts and nuts in the entire structure, or try to grasp the concept on how the system 
functions?  
We asked ourselves this question when trying to unravel the hidden systems within the ILC 
transcriptomes. To answer it, instead of only focusing on the analysis of single genes 
obtained by differential expression (DE) analysis, we integrated DE to weighted gene co-
expression network analysis (WGCNA), in order to understand how genes interact in the 
various ILC cells states discovered via dimensionality reduction and clustering. WGCNA 
calculates the interaction patterns between co-expressed genes, and places them into modules 
(i.e. networks of co-expressed genes). We manually tweaked the number of modules in order 
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module was scored based on its contribution to the explanation of metadata (e.g tissue type 
correlation, cell type correlation, etc).  
This approach allowed us to distinguish the circulatory modules in the blood (rich in 
migration-associated transcripts such as SELL, S1PR1, ITGB2, ICAM3) to the resident 
transcriptome in colon and lung (expressing CD69 transcripts, among others), with tonsil 
displaying features linked to both migration and tissue residency (Paper III, Figure 2d). Some 
of the key transcripts were validated on the protein level on blood, colon and tonsil tissues 
(CD62L, CD18, CD69, and NKp44) (Paper III, Figure 2e-g), confirming our findings in 
silico.  
Four main modules specified shared characteristics with tonsil, lung and colon ILC3. Several 
transcripts were shared between lung and colon ILC3, with CSF2, CXCL8, BHLHE40 and 
several HLADR/DP/DQ transcripts reflecting the active status of the cells. The prototypic 
ILC3 genes RORC, IL1R1, KIT were highest in a module mostly associated with colon ILC3. 
Tonsil and colon ILC3 gene networks showed similarities, with the presence of IL23R, NRP1, 
TOX, NCR2, TNFSF13B and LTB4R transcripts, the latter displaying a possible role of ILC3 
in leukotriene metabolism, also present in protein form in colon ILC3 (Paper III, Figure 3c).   
One leading module linked ILC2 from blood, tonsil and lung tissue, by displaying the 
classical transcripts defining ILC2, like GATA3, MAF, PTGDR2, HPGD and HPGDS. A 
second module was non-specifically associated with ILC2, displaying ties with ILC1 as well, 
and presenting transcripts such as IL10RA, PTGER2 and ANXA1. Interestingly, the third 
module associated with ILC2 revealed a gene-network present in lung ILC2, specifically 
lacking PTGDR2 expression (encoding the CRTH2 protein) and presenting activation 
markers like IL13, IL1RL1, IL17RB and PPARG, hinting to the possibility of activated ILC2 
losing their prototypical marker (CRTH2) when active. We confirmed this hypothesis by 
sorting and exposing blood ILC2 to an activating cytokine cocktail, which indeed 
downregulated the expression of surface CRTH2 protein, also hinting to the possibility for 
blood ILC2 to migrate to lung and downregulate CRTH2 under alarmin influence, as 
suggested in mouse models 211 and a human allergen provocation study 212. Another transcript 
highly expressed in this module and specific to active ILC2 in the lung was SLAMF1, a 
marker we already stumbled upon in Paper II that is present in activated blood ILC2. In 
tissues, SLAMF1 can possibly replace CRTH2 as an ILC2 marker, given its high specificity 
to this ILC subgroup (Paper III, Figure 4b). This remains to be explored.  
The core ILC1 module was rich in T cell related transcripts, such as CD3D/E/G, CD4, CD5 
and CD6, confirming previous reports 15,39. One other module showed the close association of 
ILC1, in particular EOMES+ ILC1, to NK cells, by presenting transcripts linked to 
cytotoxicity, such as GZMM, CD8A and CTSW, together with Paper I’s favorite transcription 




Predicted VDJ recombination analysis disentangles blood ILC1 heterogeneity 
Given the numerous T cell related transcripts in blood ILC1 (Paper III, Figure 6b, core ILC1 
module), we analyzed the blood dataset for V(D)J recombination via MIXCR 213, having 
CD4+ T cells from the same blood donors sorted in parallel as a population of comparison.  
As expected, CD4+ T cells presented mostly predicted AB chain rearrangement, with ILC2 
and B_nILC having limited predicted rearrangement. On the other hand, B_ILC1 and 
EOMES+ILC1 exhibited a combination of α/β, γ/δ and single rearranged chains, confirming 
the speculations on these cells being by some degree associated with T cells (Paper III, Figure 
7a and S7a).  
When merging CD4+ T cells and ILC, UMAP analysis revealed B_ILC1 clustering either 
with the CD4+T cells (B_ILC1 exhibiting a predicted TRA_B rearrangement) or in a separate 
cluster (B_ILC1 displaying TRG_D predicted rearrangement) (Paper III, Figure 7b-c). 
EOMES+ILC1 clustered in between CD4+T cells and CXCR3+ Th1 T cells. When running DE 
analysis on the separate clusters based on predicted chain rearrangements, AB_ILC1 
expressed transcripts of TRα and β constant and variable region, together with the CD4 
transcript. GD_ILC1 expressed transcripts of TCRδ and γ constant and variable regions, 
together with the transcription factor IKZF2 (encoding for Helios). EOMES+ILC1 expressed 
transcripts for TCRα and β constant and variable regions together with CD8A transcripts. 
Clonal analysis resulted in most cells representing unique clones, with the exception of two 
ILC1 which clones were shared with CD4+ T cells. 
V(D)J recombination analysis sheds some light on the possible origins of B_ILC1, with ILC1 
with clonal overlap to CD4+T cells most likely being T cell contaminants and ILC1 with an 
α/β-TCR rearrangement clustering with CD4+T cells possibly being “failed CD4+ T cells”. 
We speculate that EOMES+ILC1 possibly resemble “failed CD8+ T cells” given their 
transcriptional profile. ILC1 with a δ-TCR rearrangement resembled immature ILC cells, 
given their naïve transcriptional profile (Paper III, Figure S7e) and that the vast δ-TCR 
rearrangement was shown to be a feature of immature murine NK cells 214.  
In mice, a recent study concluded the possibility for lung ILC2 in homeostasis to be of T cell 
origin, since these cells display a similar TCR gene rearrangement to γδ T cells. Upon closer 
inspection, mouse lung ILC2 were shown to undergo TCRγ rearrangement but failed to 
express it, and ineffectively recombined the TCRδ locus. They propose that cells failing to 
rearrange their TCR gene, or are incapable to expressing a functional TCR, could cause T cell 
development to stop, and re-direct those cells to an ILC2 lineage 215.  
Given the data presented in Paper III, this report raises questions: could the same apply to 
human ILC1? Considering the multitude of T cell related markers expressed on ILC1 (Paper 
III, Figure 6b, module 32), it certainly seems that ILC1 are linked to T cells. Thymic and cord 
blood ILC have been shown to express intracellular CD3ε and surface CD5, the former a 
marker indicating immaturity 216. As a subset of blood ILC1 also expresses CD5 and has a 
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predicted TCR rearrangement, it could fit the profile of a T cell with halted development that 
is re-routed into the ILC lineage. Moreover, CD3ε overexpression has been linked to failed T 
cell development, when TCR is absent 217 . Given this subset’s failed T cells origin, under the 
right conditions, could it up-regulate a TCR on the surface? Published reports show that a 
very low percentage of cultured blood ILC1 in vitro have even been shown to express 
TCRα/β at the surface, although after prolonged culture and 15. Such cells could be T cell 
contaminants. In Paper III, a few cells sharing clonality with CD4+ T cells from the same 
donor could be part of this subset, and if cultured for a prolonged period, they might express 
TCR on the surface. This remains to be explored. 
Interestingly, expression of recombination activating enzymes RAG1 and RAG2, known to 
mediated V(D)J gene recombination, is lacking in ILC (data not shown). In thymocyte 
development, RAG expression is turned on and off at different maturation steps 218. It is 
activated in the first stages to start the rearranging process; if maturing B/T cells do not meet 
certain requirements (e.g. failure to express antigen receptor) they undergo apoptosis. When 
taken together, the V(D)J rearrangements results in blood ILC from Paper III and the 
speculations from recent reports in mice hint to the possibility for maturing thymocytes with 
down-regulated RAG to escape T cell development, apoptosis, and commit to the ILC 
lineage, making these cells presumed “failed T cells”.  
It is also intriguing to see how RAG-/- mice have disturbed ILC frequencies, even though 
RAG is not expressed in ILC 219,220,221. Moreover, such mice has been reported to have a 
challenged NK cell cellular fitness. More studies are needed to understand the functional 
consequence that RAG deficiency has on ILC, and its impact on cellular fitness 222,223. 
Since a subset of blood ILC1 expresses CD4 or CD8 at the surface 15, one wonders how these 
ILC1 with rearranged TCR, if they are failed T cells, could escape apoptosis while 
undergoing pro-T/pre-T/double negative and double positive steps in the thymus without a 
working antigen receptor, escape from the thymus and end up in circulation. A down-
regulation of the TCR after thymic education? A bold research approach is needed to answer 
such questions. 
With scRNA technology we can only “predict” the rearrangement of TCR in ILC1, given that 
the receptors are not actually expressed on the membrane. A possible approach to analyzing 
an expressed TCR, might involve culturing blood ILC in vitro and perform experiments on 
the resulting TCR expressed on ILC surface. 
More research is needed on this topic to better understand this issue. 
Trajectory analysis defining ILC3 transcriptional states 
As shown in earlier chapters and in Paper I, ILC are very plastic, and they can adopt 
dynamic identity changes following the microenvironment or lineage specification during 
development. Although scRNA-seq methodology allows the researcher to only capture a 
single picture of the cell status at a given time, transcriptome analysis enables the 
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reconstruction of cellular trajectories by arranging cellular states along a pseudo-temporal 
axis, an abstract scale of maturation. In Paper III, Slingshot v1.2.0 package was used for 
trajectory inference 224. Since some dimensionality reduction methods can create a distorted 
representation of the original space (e.g UMAP, t-SNE), diffusion maps (DM) embeddings 
were used, as they more accurately represent gradual identity changes, allowing the 
identification of differentiation trajectory on scRNA-seq data 225. A minimum spanning tree 
(MST) was created on the DM clusters to determine the number of lineages and bifurcation 
points present in the dataset, using its longest path as a backbone for the pseudotime axis. The 
naïve cluster (nILC for lung and colon, cluster 4 for tonsil and B_nILC for blood) was set as 
root, given its transcriptome profile naivety.  
Trajectory analysis identified high heterogeneity among ILC3 in the colon, lung and tonsil, 
inferring potential maturation levels between subclusters, as identified by Louvain clustering 
(Figure 12, colon ILC3a-d, lung ILC3a-b, tonsil ILC3a-b). When comparing clusters through 
MAST differential expression, we could identify activated subsets (colon ILC3a-b, lung 
ILC3a-b, tonsil ILC3a), defined by the presence of transcripts such as XCL1, XCL2, CXCL2 
and CXCL8, molecules involved in chemotaxis, CSF2, coding for the effector molecule GM-
CSF, and CCL20, associated with the chemokine CCR6. A naïve-like ILC3 subset was 
identified in tonsil (ILC3b), and a lymphoid structure related subset in colon (ILC3d). These 
subsets were defined by transcripts associated with naivety and migration, such as SELL and 
S1PR1, respectively.  
  
Figure 12. Graphical summary of Paper III approach and main findings. 
In summary, we analyzed ILC from blood, tonsil, lung and colon tissues, for a total of 2956 
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heterogeneity and their subset and tissue transcriptional imprinting. Gene co-expression 
network analysis divided the total diversity of the dataset into 100 networks of gene, which 
identified ILC transcriptional networks. VDJ recombination analysis was successful in 
disentangling ILC1 heterogeneity, linking ILC1 to possibly failed T cells, and immature ILC 
cells. Through trajectory analysis we were able to identify a high degree of transcriptional 
heterogeneity given the variable activation status of ILC3 subgroups in tonsil, lung and colon.  
In conclusion, Paper III supported the field’s attempt to characterize ILC heterogeneity by 
offering interesting results and a vast dataset that will lay the foundation to future studies 



















































6 CONCLUDING REMARKS 
In the past two decades, the ILC field has advanced tremendously, from the discovery of the 
main ILC subsets to an understanding of their plastic behavior and development. Many 
questions remain unanswered, especially when it comes to human biology, given the 
challenge in obtaining tissues from patients for experimental purposes. The findings 
presented in this thesis, mainly on ILC residing in several human tissues, represent a small 
but important step forward in the field, and provide publically available datasets for future 
studies aiming at broadening the understanding of ILC function further. Listed below is a 
summary of the key findings from each of the three papers: 
• In Paper I we could show that tonsil ILC3 under inflammatory conditions can trans-
differentiate into different flavors of ILC1 and NK cells, building on previous reports. 
This transdifferation was markerd by the expression of IKZF3, encoding Aiolos. By 
silencing this transcription factor via Lenalidomide, an anticancer drug specifically 
targeting Ikaros family members, ILC3 to ILC1 differentiation was decreased. This 
also triggered an increased level of activation in Lenalidomide-treated cultured ILC3, 
resulting in enhanced IL-22 release. Specific drug-targeting of ILC with an Aiolos 
silencing drug could provide to be useful in patients with conditions like IBD, where 
ILC3 to ILC1 transdifferentiation is likely to occur, halting ILC1 release of 
inflammatory elements contributing to the inflammatory environment in the gut.  
• In Paper II we characterized ILC in a large cohort of blood samples from patients 
sufferring from IBD and used blood samples from healthy donors for comparison. We 
detected an overall activated profile of ILC in CD and/or UC samples, examplified by 
the presence of NKp44, CD56 and HLA-DR on ILCs, and the lack of markers 
associated with naivety, such as CD45RA. Of note, we found an increased frequency 
of SLAMF1+ILC2 in CD patients, which was correlated with reduced CD activity in 
CD active patients. We speculate that this population is an activated mature form of 
ILC2, given its high CRTH2, CD161 and GATA3 expression and IL-13 production 
capabilities. More research is needed to define the function of this population further. 
• In Paper III, through scRNA-seq technology we were able to shed light on ILC 
heterogeneity in blood, tonsil, gut and lung tissues at homeostasis. Through 
dimensionality reduction and clustering we were successful in identifying several 
subpopulations of ILC, some more heterogeneous than others, displaying a range of 
migratory (blood ILC) and tissue resident (lung and colon ILC) features, with tonsil 
ILC sharing characteristics of both. Data clustering revealed a naïve ILC subset in the 
lung and colon tissues, most likely giving rise to more mature subsets, as illustrated 
by trajectory analysis. V(D)J recombination analysis in blood predicted 
recombination in ILC1, dividing the cells into several clusters. Through differential 
expression analysis, ILC to CD4+/CD8+ T cell and NK cell comparison, we could 
define such clusters, speculating on the mystery of the likely origin of ILC1, from 
contaminants, to failed T cells or immature ILCs. Overall, we provide a large dataset 
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of ILC, T and NK cell transcriptome at full-length, giving the field an opportunity to 
analyze it further. 
 
6.1  FUTURE DIRECTIONS 
Although the ILC field has progressed tremendously during my time as a PhD student, many 
questions remain unanswered, creating an opportunity for researchers to fill in the gaps in 
ILC-mediated immunity knowledge and understanding.  
Possible ideas branching from the projects presented in this thesis could include continuing 
the investigation on the effects of the Ikaros family of TF on human primary ILC, building on 
Paper I’s results, by looking at single TF roles in ILC development and function. In order to 
do that efficiently, a stable and reliable gene knockdown/silencing system needs to be 
researched. Considerable efforts were made in setting up such a system during Paper I’s data 
collection period, but human primary ILC proved to be a tough subset to efficiently transfect. 
Viral-based transfection could be a way to do that effectively. Validating Aiolos’ knockdown 
effects on ILC3-ILC1/NK trans-differentiation without the parallel silencing of Ikaros (due to 
Lenalidomide’s dual targeting) would be exciting indeed. Based on the results of such an 
approach, creating a system that specifically targets the Aiolos protein in ILC of IBD patients 
would represent a nice system to slow down ILC3 to ILC1/NK cells trans-differentiation, 
effectively dampening inflammation. 
Building on Paper II, it would be interesting to collect more samples from the IBD and HC 
cohorts, genotype them and evaluate ILC subsets frequencies via FACS in parallel. The aim 
would be to assess the determinants of immunologic variance by checking for genotype 
versus phenotype correlations, in order to quantify the contribution of host genetics to IBD. 
In order to have enough statistical power for such a project, a cohort in the hundreds of 
samples would be needed, making this effort considerable for clinicians involved in patient 
recruitment and sample collection, together with the research group involved in the lab. As 
FACS technology keeps improving, the detection of >30 parameters parameters is now a 
reality. Thanks to this technology, the project could investigate several immune subsets, 
without being restricted to ILC only.  
A continuation of Paper III could include a comparison between ILC/T/NK cells from the 
published healthy colon data, to new data of the same subsets in IBD patients. Such a study 
could possibly reveal novel transcripts differentially expressed in IBD patients. The 
optimized knockdown system mentioned above could be adopted to efficiently investigate 
such transcripts and isolate possible mechanisms of protein functions in vitro. It would also 
be of interest to perform V(D)J rearrangement analysis on inflamed gut ILC1, to examine if 
such ILC1, possibly “ex-ILC3” that have gone through trans-differentiation, have a 
rearranged TCR.  
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More generally, future prospectives in the ILC field will most likely rely more on synergetic 
efforts between bioinformatics and biological research, with cutting-edge technologies 
providing new ways to tackle biological questions. As single cell sequencing is getting more 
and more accessible, and considerably cheaper, the amount of cells analyzed will only 
increase, with better sequencing methodologies being proposed (Smart-seq3, 10x v3, among 
others), giving higher cell recovery rates, read numbers and overall quality. As in silico 
methodologies are now able to integrate datasets of different origin (donor or even species), it 
will be exciting to unravel questions not answerable in the past, especially when it comes to 
rare populations of cells like ILC, in even rarer human tissues.  
Applying one -omic technology will soon not be enough to push the field forward. We need 
to understand how ILC are shaped by their surroundings, by looking at their metabolism, 
their genetic influence, interactions with other molecules, at a higher scale. New approaches 
involving a synergetic combination of -omics will most likely take over, forcing inter-field 
collaborations in order to effectively decipher the multi-layered results. Such studies will 
provide a more unbiased and systematic approach to ILC biology, and more broadly to 
immunological research. The three articles presented in this thesis, with emphasis on Paper 
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8 FUN STATS 
Tonsil processed: 124 
Buffy coats processed: 15 
Gut biopsies processed: 64 
Lung biopsies processed: 5 
Antibody tubes + MACS beads + cytokines vials used: 444 
Number of FACS experiments: 363 
Number of sorted samples (BD AriaIIu, Aria III, Aria FUSION, Melody and Sony): 90 
Single cell sorted 384-well plates: 52 
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